MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
IDEXX Laboratories Operating Income 2011-2026 | IDXX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income IDEXX Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.36 B | 1.13 B | 1.1 B | 899 M | 932 M | 695 M | 553 M | 491 M | 413 M | 350 M | 300 M | 260 M | 267 M | 263 M | 236 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.36 B | 236 M | 616 M |
Quarterly Operating Income IDEXX Laboratories
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 355 M | 373 M | 317 M | - | 304 M | 264 M | 299 M | - | 275 M | 296 M | 280 M | - | 245 M | 179 M | 248 M | - | 226 M | 259 M | 248 M | - | 172 M | 193 M | 144 M | 116 M | 140 M | 164 M | 133 M | 115 M | 117 M | 146 M | 113 M | 97.8 M | 100 M | 123 M | 92.2 M | 83.8 M | 88.5 M | 104 M | 73.8 M | 66.9 M | 71.9 M | 88.3 M | 72.8 M | 34.8 M | 72.2 M | 83.2 M | 70 M | 61.3 M | 65.5 M | 78.8 M | 61.2 M | 63.4 M | 62.9 M | 75.8 M | 60.4 M | 55.3 M | 56.1 M | 71.3 M | 53.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 373 M | 34.8 M | 145 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 115.19 | 0.1 % | $ 35 B |  USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.14 | 0.44 % | $ 6.21 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.2 | 0.56 % | $ 174 M |  China |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 16.29 | 1.46 % | $ 868 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.41 | 2.92 % | $ 1.88 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 2.25 | -2.17 % | $ 9.95 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 23.05 | -0.35 % | $ 640 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 175.38 | -0.17 % | $ 8.69 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 498.64 | 1.04 % | $ 14.4 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 190.7 | 0.6 % | $ 136 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.47 | 2.64 % | $ 414 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 122.51 | 1.3 % | $ 19.5 B | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.94 | 3.19 % | $ 1.02 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.95 | 3.57 % | $ 452 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 78.76 | 0.2 % | $ 9.87 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.77 | 2.97 % | $ 89.9 K | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.07 | -3.19 % | $ 4.75 M | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 28.27 | -0.12 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 107.75 | 0.88 % | $ 8.89 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 261.97 | 0.4 % | $ 21.8 B | USA |
 |
Natera
NTRA
|
-541 M | $ 199.83 | 3.52 % | $ 19.7 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 118.95 | 1.55 % | $ 5.56 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.67 | -0.15 % | $ 278 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 80.99 | 0.5 % | $ 5.47 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 192.07 | 0.29 % | $ 21.3 B | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.58 | -0.1 % | $ 2.67 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.19 | -2.46 % | $ 1.99 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.76 M | $ 5.0 | 1.21 % | $ 3.94 M | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |